Increasing HPV vaccine uptake among young patients
Human Papillomavirus Ends Here: A Multilevel Intervention to Increase Uptake of the HPV Vaccine Among Adolescents
This study is testing a new approach to help more young patients aged 10-12 get the HPV vaccine at clinics in California.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 2232 (estimated) |
| Ages | 10 Years to 12 Years |
| Sex | All |
| Sponsor | University of California, Davis Academic / other |
| Locations | 1 site (Sacramento, California) |
| Trial ID | NCT06831929 on ClinicalTrials.gov |
What this trial studies
This study aims to develop and evaluate a culturally tailored multilevel intervention designed to increase the uptake of the HPV vaccine among eligible patients aged 10-12 at the University of California, Davis Health Community Physician practices. The intervention will be refined through qualitative interviews with stakeholders and implemented in a randomized controlled trial across twelve clinics. The effectiveness of the intervention will be assessed by comparing HPV vaccine completion rates between the intervention and control groups using electronic medical records.
Who should consider this trial
Good fit: Ideal candidates for this study are patients aged 10-12 who are eligible for the HPV vaccine.
Not a fit: Patients who have already received the HPV vaccine or have contraindications to it will not benefit from this study.
Why it matters
Potential benefit: If successful, this intervention could significantly increase the HPV vaccination rates among adolescents, leading to better prevention of HPV-related diseases.
How similar studies have performed: Other studies have shown success in increasing vaccination rates through tailored interventions, suggesting that this approach may be effective.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: • Clinic patients between the ages of 10-12 who are eligible for the HPV vaccine Exclusion Criteria: • Clinic patients who already received the HPV vaccine or with any contraindication to the HPV vaccine.
Where this trial is running
Sacramento, California
- University of California Davis Health — Sacramento, California, United States (Recruiting)
Study contacts
- Principal investigator: Julie HT Dang, PhD — University of California, Davis
- Study coordinator: Ramneek Kahlon, BS
- Email: rkahlon@ucdavis.edu
- Phone: 9167312578
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.